There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.
References:
1) http://www.who.int/mental_health/managem... date accessed 18 May 2018 2) https://www.epilepsy.com/learn/about-epilepsy-basics/who-get... date accessed 18 May 2018 3) ILAE official report: a practical clinical definition of epilepsy. Epilepsia. [https://www.ncbi.nlm.nih.gov/pubmed/2473... ] 2014 Apr;55(4):475-82. doi: 10.1111/epi.12550. Epub 2014 Apr 14. (https://www.ncbi.nlm.nih.gov/pubmed/2473...) date accessed 18 May 2018
CONTACT: For further information: Corporate Communications, FranceNivelle, Global Communications, UCB, T+32-2-559-9178,France.nivelle@ucb.comJim Baxter, Neurology Communications, UCB, T+32-2-473-78-85-01,jim.baxter@ucb.comLaurent Schots, Media Relations, UCB, T+32-2-559-92-64,laurent.schots@ucb.comInvestor RelationsAntje Witte, Investor Relations, UCB, T+32-2-559-94-14, antje.witte@ucb.comIsabelle Ghellynck, Investor Relations, UCB, T +32-2-559-9588,isabelle.ghellynck@ucb.com
